The Asia Pacific Herpes Simplex Virus Treatment Market would witness market growth of 3.9% CAGR during the forecast period (2022-2028).
Herpes medicine is available in topical treatment forms, the demand for which is continually rising. There are topical cream versions of acyclovir and penciclovir on the market. Pain lasts about four days but is cut short to three and a half days when penciclovir cream is used every two hours. While topical formulations are well-liked, they are not meant to treat herpes simplex. In order to hasten the healing of sores, they are typically administered to alleviate discomfort and agony. Also, topical formulations are user-friendly, making them practical and highly appreciated by diverse consumers.
In addition to increasing the risk of HIV infection and transmission, HSV can cause serious side effects, including keratitis and encephalitis in those suffering from chronic or long-term conditions. This is one of the key factors causing the rise in demand for HSV therapy, especially in light of the rising prevalence of chronic conditions. In addition, when a baby is infected with HSV during delivery in the genital tract, a dangerous illness called neonatal herpes can develop. Therefore, the market benefits from the increased birth rates because neonatal herpes can result in long-term cognitive impairment or infant mortality.
Development is anticipated to be supported by the increased herpes prevalence in developing nations like China and India. Because there are so many regional businesses, the market is fragmented, contributing to the greater adoption rate of generics for the treatment of herpes. Also, the demand is rising due to increased attempts to create a vaccine as a precautionary step to reduce the spread of infection. Therefore, due to advancements in industry infrastructure, an increase in disposable income, and a well-established establishment of domestic companies in the region, Asia-Pacific presents lucrative opportunities for key participants operating in the herpes simplex virus treatment market.
The China market dominated the Asia Pacific Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $164.8 Million by 2028. The Japan market is estimated to grow a CAGR of 3.2% during (2022 - 2028). Additionally, The India market would exhibit a CAGR of 4.6% during (2022 - 2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Herpes Simplex Virus Treatment Market is Projected to reach USD 2.1 Billion by 2028, at a CAGR of 3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
By Drug Type
By Type
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
